The accuracy of fecal immunochemical tests (FITs), which are widely used for bowel cancer screening, have been examined following exposure to different temperatures using laboratory and field ...

Although considered a single class, fecal immunochemical tests (FITs) vary in their ability to detect advanced colorectal neoplasia (ACN) and should not be considered interchangeable, new research ...

Commercially available noninvasive screening tests for colorectal cancer - a fecal immunochemical test (FIT) and the multi-target stool DNAtest (mt-sDNA; or Cologuard ®) - are equally effective for ...

About The Study: This study found that comparable levels of sensitivity and specificity as reported for the multitarget stool RNA (mt-sRNA) test in the colorectal cancer (CRC)-PREVENT study could be ...

A little-known at-home test can detect early-onset colon cancer before symptoms develop, increasing the chance of surviving a disease that is surging among young people. The fecal immunochemical test ...

About The Study: In this nested case-control study, completing fecal immunochemical test was associated with a lower risk of overall death from colorectal cancer, particularly in the left colon, and ...

Fecal immunochemical testing (FIT) is a non-invasive screening modality that quantifies haemoglobin levels in stool to detect occult bleeding from colorectal neoplasia. By offering a simple home-based ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

Colorectal cancer (CRC) remains the second leading cause of cancer-related deaths in the United States, a troubling fact when considering that CRC is largely preventable and treatable if caught early.

Routine screening with fecal occult blood testing (FOBT) is associated with a decrease in colorectal cancer (CRC) mortality, according to a study published online Feb. 27 in JAMA Network Open.

This week's topics include semaglutide and mortality, beta-blockers after myocardial infarction (MI), comparing fecal immunochemical tests (FITs), and 30-year cardiovascular disease (CVD) prediction ...